
FDA Proposes Excluding Novo, Lilly Weight Loss Drugs from Compounding List
The FDA has proposed excluding the active ingredients of major weight loss and diabetes drugs from Novo Nordisk and Eli Lilly from the list used for bulk compounding. This action aims to limit the creation of cheaper, compounded alternatives unless the drugs are officially designated as being in shortage. The agency cited a lack of "clinical need" for compounding these specific medications. The proposal affects 503B outsourcing facilities and is subject to public comment until late June. The move follows significant investments by the pharmaceutical companies to increase supply and improve affordability.






















